The phase 1b LORDSHIPS study has suggested a potentially synergistic anti-tumor effect with pyrotinib, letrozole, and dalpiciclib in front-line patients with HR-positive, HER2-positive metastatic breast cancer15. This evidence concerns the gene ERBB2 and neoplasm.